ABSTRACT
BACKGROUND:
Current regulation of drug approvals has caused considerable controversy as entrusted to the National Institute of Clinical Excellence, and has led to a lack of availability of modern medicines on the basis of calculations made of 'value'.AIM:
We have examined the assessment tool used by National Institute of Clinical Excellence (NICE) to establish the cost of drugs in order to assess whether it is a reasonable and objective evaluation methodology.DESIGN:
A review of the methods of analysis.METHODS:
An objective assessment of the value of the Quality Adjusted Life Year (QALY).RESULTS:
We conclude that current methods used by NICE to assess drug costs are arbitrary, subjective and fail to reflect the true costs for patients, which are grossly overestimated.CONCLUSION:
NICE needs to look again at the evaluation methods for calculating drug costs, and change their methodology from a subjective to an objective measure of true cost.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Technology Assessment, Biomedical
/
Drug Costs
/
Quality-Adjusted Life Years
Type of study:
Clinical_trials
/
Guideline
/
Health_economic_evaluation
/
Health_technology_assessment
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
QJM
Journal subject:
MEDICINA
Year:
2010
Document type:
Article